z-logo
Premium
Three‐Year Results of Facial Photoaging in Asian Patients After Alexandrite 755 nm Picosecond Laser With Diffractive Lens Array: A Split‐Face, Single‐Blinded, Randomized Controlled Comparison
Author(s) -
Yu Wenyou,
Zhu Jiafang,
Yu Wenxin,
Shang Ying,
Lyu Dongze,
Lin Xiaoxi,
Xu Hui,
Zhang Zhen
Publication year - 2021
Publication title -
lasers in surgery and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 112
eISSN - 1096-9101
pISSN - 0196-8092
DOI - 10.1002/lsm.23393
Subject(s) - photoaging , dermatology , medicine
Background and Objective The long‐term efficacy of a picosecond alexandrite laser (PSAL) with a diffractive lens array (DLA) for the treatment of photoaging is absent. To observe the long‐term efficacy of PSAL for the treatment of photoaging. Study Design/Materials and Methods Each patient ( n  = 10) received 10 treatments at 2‐week intervals. One side of the face was randomly selected for treatment. At 1, 3, 6, and 36 months after the final treatment, two blinded physicians evaluated photographs with four clinical indicators of photoaging (dyschromia, skin texture, skin laxity, and rhytids). A quartile scale was used. Results At baseline, there were no significant differences in dyschromia, skin texture, facial laxity, or rhytids between the treated and control sides ( P  > 0.05). Picosecond laser‐treated side showed 0.85 and 1.05 (both P  < 0.05) better for dyschromia at 3‐ and 6‐month follow‐up, and 0.6 ( P  < 0.05) better for skin texture at 6‐month follow‐up. At 36‐month follow‐up, the degree of photoaging is intensified on the control side while the rejuvenation efficacy maintained on the treated side, with 1.4, 0.75, and 0.8 (all P  < 0.05) better for dyschromia, skin texture, and rhytids relative to the control side measures. Conclusion Our results demonstrate the long‐term efficacy and safety of PSAL with DLA for the treatment of facial photoaging. Limitation: Small sample size and the lack of objective evaluation. Lasers Surg. Med. © 2021 Wiley Periodicals LLC

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here